IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis study tests a new tablet called HSK44459 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if t…
Matched conditions: IPF
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New inhaled drug for lung scarring takes first step in healthy people
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and tolerability of RC010, an inhaled powder drug, in 42 healthy Chinese adults aged 18-55. RC010 is being developed to treat idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Participants receive single rising doses to …
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Nanjing Reju Therapeutics Co., Ltd • Aim: Knowledge-focused
Last updated May 11, 2026 20:51 UTC
-
New IPF drug candidate tested in healthy people for first time
Knowledge-focused Not yet recruitingThis early-stage study tests the safety of a new tablet called HW252001 in 98 healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather safety information, n…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated May 11, 2026 20:48 UTC